Roche ends small cell lung cancer trials as results show ‘reduced efficacy’
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.
Drugs
Health
Pharma
Drugs
Health
Pharma
FDA rejects Daiichi, Merck, antibody-drug conjugate application
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.
Drugs
Health
Pharma
US regulator clears Merck’s lung therapy after ‘significant’ results
HQ Team March 27, 2024: The US regulator, the Food and Drug Administration, has approved Winrevair therapy of Merck & Co., Inc., to.
Drugs
Health
Pharma
Merck to buy Harpoon for $680 million to step up cancer portfolio
HQ Team January 8, 2024: Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio —.
Drugs
Health
Pharma
Merck & Co meets breast cancer therapy goal in last-stage trials
HQ Team July 29, 2023: Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of.
Drugs
Pharma
Verge Genomics starts human trials with AI drug
Verge Genomics, backed by Eli Lilly and Merck & Co., announced it had dosed a human during clinical trials with a drug discovered.